Alice Shaw

Alice Shaw at Massachusetts General Hospital (now at Relay Therapeutics) led clinical development of crizotinib and next-generation ALK inhibitors for ALK-rearranged lung cancer, defining the precision oncology paradigm for this molecular subset. Her work on ALK resistance mechanisms including secondary mutations and bypass signaling drove development of second and third-generation ALK inhibitors. She contributed to defining the optimal sequencing strategy from alectinib to lorlatinib for ALK+ NSCLC. Her career is a model for how a molecular alteration can be tracked through multiple generations of targeted therapy.